Keenova Reports Second Quarter 2026 Financial Results

Phase 3positiveActhar® GelXIAFLEX®PercocetPositive

AI Analysis

Summary

Keenova reported Q2 2026 results with strong growth in Acthar Gel and XIAFLEX. The company announced positive Phase 3 data for XIAFLEX in plantar fibromatosis, supporting a planned sBLA submission in Q4 2026, and initiated a Phase 3 hammer toe study in Q3 2026.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Positive Phase 3 Plantar Fibromatosis data

Importance:6/10

Sentiment:

0.60

Phase_3_datapipeline_advancementXIAFLEXplantar_fibromatosissBLA_submissionhammer_toeearnings

Read the original article

Published by PR Newswire Biotech on August 11, 2026 10:30 AM

Read Original